CND Life Sciences has opened a dedicated Innovation Laboratory in Scottsdale, separate from its clinical testing operations, to advance assay development, biomarker research and translational programs. The company's Syn-One Test identifies phosphorylated alpha-synuclein in cutaneous nerves and quantifies peripheral nerve degeneration, and has been used in the diagnostic evaluation of more than 70,000 patients. Dedicated infrastructure for biomarker discovery signals continued movement toward minimally invasive detection of neurodegenerative disease.
Key Points
- Innovation Laboratory separated from CLIA-certified clinical operations to accelerate biomarker rese
- Syn-One detects phosphorylated alpha-synuclein in skin nerve fibers
- Over 70,000 patients evaluated by more than 3,500 clinicians
Longevity Analysis
Neurodegenerative disease has historically been identified late, after substantial and irreversible loss of neural tissue. A skin-based assay that quantifies peripheral nerve degeneration shifts detection toward the periphery, where pathological protein accumulation appears years before motor or cognitive signs become apparent — turning a diffuse, easily misattributed set of symptoms into a measurable signal. Dedicated capacity for assay development matters because the value of such markers depends on repeatability over time, allowing clinicians to track trajectory rather than confirm a diagnosis already evident on examination.
Original published by LT Wire.